UK launch for Bial’s Parkinson’s drug
Patients with Parkinson’s disease in the UK can now potentially access a new option to treat motor fluctuations with the launch of Bial’s Ongentys across the country.
Read More
Tag: Ongentys
EU clears Bial’s new Parkinson’s drug
The European Commission has approved Bial’s Ongentys for Parkinson’s disease patients with motor fluctuations.
Read More
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
